Código QR

Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer

Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD). Both full‐length AR and truncated AR‐Vs require a f...

Descrición completa

Gardado en:
Principais autores: Yukiyoshi Hirayama, Teresa Tam, Kunzhong Jian, Raymond J. Andersen, Marianne D. Sadar
Formato: Artigo
Idioma:Inglês
Publicado: Wiley 2020-10-01
Series:Molecular Oncology
Assuntos:
androgen receptor
AR‐V7
combination therapy
CRPC
EPI‐002
ralaniten
Acceso en liña:https://doi.org/10.1002/1878-0261.12770
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares